Table 2.
Risk of COVID-19 breakthrough infection among SARD patients who received either BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) vaccine
| Population | Number of COVID-19 breakthrough infection events | Mean follow up, months | Incidence ratea, per 1000 person-months | Rate differencea (95%CI), per 1000 person-months | Hazard ratioa (95%CI) BNT162b2 vs mRNA-1273 | |||
|---|---|---|---|---|---|---|---|---|
| BNT162b2 | mRNA-1273 | BNT162b2 | mRNA-1273 | BNT162b2 | mRNA-1273 | |||
|
| ||||||||
| N | 5516 | 4322 | 5516 | 4322 | 5516 | 4322 | ||
| Primary analysis | ||||||||
| Any infection | 446 | 329 | 11 | 12 | 6.83 | 6.12 | 0.71 (−0.70, 2.12) | 1.12 (0.90, 1.39) |
| Sensitivity analyses | ||||||||
| Pre-Omicron (12/15/2021) | 158 | 94 | 9 | 10 | 2.89 | 2.16 | 0.73 (−0.24, 1.71) | 1.34 (0.91, 1.98) |
| Censor at 3rd vaccine | 212 | 132 | 8 | 9 | 4.22 | 3.36 | 0.82 (−0.43, 2.07) | 1.31 (0.94, 1.83) |
| Pre-Omicron and censor at 3rd vaccine | 118 | 71 | 8 | 8 | 2.49 | 1.95 | 0.55 (−0.45, 1.55) | 1.33 (0.84, 2.09) |
| Negative control analyses | ||||||||
| Infection within 10 days of first vaccine | 6 | 5 | 12 | 12 | 0.06 | 0.09 | −0.03 (−0.18, 0.12) | 0.67 (0.09, 5.28) |
| Death due to non-COVID-19 causes | 97 | 60 | 11 | 12 | 1.28 | 1.27 | 0.01 (−0.61, 0.63) | 1.01 (0.62, 1.64) |
a
Time-stratified PS overlap weighted
Propensity score model: covid prior to index date, age, sex, race, ethnicity, BMI, smoking status, Charlson
Comorbidity Index, rheumatic disease diagnosis, immunomodulatory medication